FDAapproval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · KRAS G12C Inhibitor
- Sub-indication
- Lung Cancer
Related signal: FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC